These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 3766490)
21. Efficacy and safety of aztreonam in the treatment of serious gram-negative bacterial infections. LeFrock JL; Smith BR; Chandrasekar P; Rolston KV; Molavi A; Kannangara W Arch Intern Med; 1987 Feb; 147(2):325-8. PubMed ID: 3813751 [TBL] [Abstract][Full Text] [Related]
22. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. Henry SA; Bendush CB Am J Med; 1985 Feb; 78(2A):57-64. PubMed ID: 3881950 [TBL] [Abstract][Full Text] [Related]
23. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. Rabinad E; Bosch-Perez A Chemotherapy; 1989; 35 Suppl 1():1-7. PubMed ID: 2659288 [TBL] [Abstract][Full Text] [Related]
25. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli. Nolen TM; Phillips HL; Hall HJ Rev Infect Dis; 1985; 7 Suppl 4():S666-8. PubMed ID: 3909321 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli. Clergeot A; Steru D; Rosset MA; Carbon C Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476 [TBL] [Abstract][Full Text] [Related]
27. Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria. Cox CE Rev Infect Dis; 1985; 7 Suppl 4():S767-71. PubMed ID: 3909335 [TBL] [Abstract][Full Text] [Related]
28. [Clinical efficacy of aztreonam in refractory infections in children]. Ogura H; Hamada F; Fujieda M; Matsumoto K; Araki K; Ogura Y; Kuramitsu M; Kurashige T; Kitamura I Jpn J Antibiot; 1985 Nov; 38(11):3349-57. PubMed ID: 4094068 [TBL] [Abstract][Full Text] [Related]
29. Treatment of serious gram-negative infections with aztreonam. Greenberg RN; Reilly PM; Luppen KL; McMillian R; Bollinger M; Wolk SM; Darji TB; Noorani AA J Infect Dis; 1984 Nov; 150(5):623-30. PubMed ID: 6541672 [TBL] [Abstract][Full Text] [Related]
30. Evaluation of aztreonam in the treatment of severe bacterial infections. Romero-Vivas J; Rodríguez-Créixems M; Bouza E; Hellín T; Guerrero A; Martínez-Beltrán J; García de la Torre M Antimicrob Agents Chemother; 1985 Aug; 28(2):222-6. PubMed ID: 3834832 [TBL] [Abstract][Full Text] [Related]
31. Efficacy of aztreonam in the treatment of neonatal sepsis. Sklavunu-Tsurutsoglu S; Gatzola-Karaveli M; Hatziioannidis K; Tsurutsoglu G Rev Infect Dis; 1991; 13 Suppl 7():S591-3. PubMed ID: 2068464 [TBL] [Abstract][Full Text] [Related]
32. [Clinical and pharmacokinetic evaluations of aztreonam in children]. Meguro H; Arimasu O; Sugamata K; Hiruma F; Sohda H; Shiraishi H; Fujii R Jpn J Antibiot; 1985 Nov; 38(11):3217-29. PubMed ID: 4094055 [TBL] [Abstract][Full Text] [Related]
33. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli. Simons WJ; Lee TJ Rev Infect Dis; 1985; 7 Suppl 4():S783-8. PubMed ID: 2934786 [TBL] [Abstract][Full Text] [Related]
38. The use of aztreonam in pediatric patients: a review. Bosso JA; Black PG Pharmacotherapy; 1991; 11(1):20-5. PubMed ID: 1902290 [TBL] [Abstract][Full Text] [Related]
39. Aztreonam activity, pharmacology, and clinical uses. Neu HC Am J Med; 1990 Mar; 88(3C):2S-6S; discussion 38S-42S. PubMed ID: 2180293 [TBL] [Abstract][Full Text] [Related]